GNLXHealthcare · BiotechnologyGNLX Stock Forecast: Genelux Corp. Price Predictions for 2026-2027
The 6 Wall Street analysts covering Genelux Corp. hold a median 12-month price target of $16 — +436.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
GNLX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Genelux Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (73): Smaller than most of the companies we track.
Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Genelux Corp. — and when they’d sell — is the membership.
GNLX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on GNLX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +436.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Mar 2026 | Benchmark | Maintains | Speculative Buy | $23 → $20 |
| 21 Oct 2025 | Lake Street | Initiates | Buy | — |
| 21 July 2025 | LUCID CAPITAL MARKETS | Initiates | Buy | — |
| 8 May 2025 | Benchmark | Maintains | Speculative Buy | — |
| 31 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Oct 2024 | Guggenheim | Initiates | Buy | — |
| 27 Aug 2024 | Roth MKM | Initiates | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 June 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 31 May 2024 | Benchmark | Maintains | Speculative Buy | — |
| 13 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Apr 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 2 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 Nov 2023 | HC Wainwright & Co. | Initiates | Buy | — |
| 24 Nov 2023 | Benchmark | Maintains | Speculative Buy | — |
| 12 Sept 2023 | Maxim Group | Initiates | Buy | — |
| 9 June 2023 | Benchmark | Maintains | Speculative Buy | — |
| 18 May 2023 | Brookline Capital | Initiates | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
GNLX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Genelux Corp. (GNLX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −3.4×
- Price / sales
- 16478.9×
- Price / book
- 5.7×
- EV / EBITDA
- −3.1×
Cheaper than 88% of US stocks
Cheaper than 1% of US stocks
Cheaper than 18% of US stocks
Cheaper than 76% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −432112.5%
- Net margin
- 0.0%
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
- Return on equity
- −127.3%
- Return on assets
- −60.6%
- Dividend yield
- —
Higher than 11% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
GNLX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GNLX appears on the weeks it earns a place.
Frequently asked questions about GNLX stock
What is the GNLX stock price forecast for 2026-2027?
The 6 Wall Street analysts covering Genelux Corp. have a median 12-month price target of $16, with estimates ranging from $10 to $31. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is GNLX stock a buy right now?
Of the 6 analysts covering Genelux Corp., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Genelux Corp. 25 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank GNLX?
As at 1 Aug 2026, Genelux Corp. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (73 of 100).
Will GNLX stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts implies +436.9% from the last close, and Ticker Nerd's factor model ranks Genelux Corp. 25 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the GNLX stock forecast for 2030?
No analyst covering Genelux Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GNLX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $31 over the next 12 months.
How has GNLX stock performed over the past year?
Genelux Corp. returned -15.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Genelux Corp. do?
Genelux Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies for patients with aggressive or difficult-to-treat solid tumor types.
About Genelux Corp.
Genelux Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies for patients with aggressive or difficult-to-treat solid tumor types. Its lead product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary modified strain of the vaccinia virus designed to selectively target and destroy cancer cells while stimulating immune responses. The company leverages its proprietary CHOICE discovery and development platform to engineer an extensive library of oncolytic vaccinia virus candidates with immune modulatory and enhanced cell-killing properties. Genelux Corp. targets cancers such as ovarian, lung, and pancreatic, addressing unmet needs in immuno-oncology through innovative virotherapy approaches. Operations are based in Southern California, with headquarters in Westlake Village. Founded in 2001, Genelux Corp. emphasizes clinical advancement of its pipeline to provide safe and effective treatments for solid tumors.
CEO Mr. Thomas D. Zindrick J.D. · 25 employees · United States · https://www.genelux.com